InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$235.00

2026-10-16

Market Cap

$25.9B

Volume

0.8M

52-Wk High

$248.84

52-Wk Low

$171.18

Trailing PE

24.6

P/S

2.24

Gross Margin

33.1%

Net Margin

9.2%

ROE

14%

ROIC

8%

Piotroski

7/9

Altman Z

3.6

1-Yr Return

+25.8%

5-Yr Return

+162.7%

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

SectorHealthcareIndustryMedical - Diagnostics & ResearchExchangeNYSEMarket Cap$25.9BEmployees57,000 (SEC-filed)CEOJames E. DavisIPO1996-12-17CountryUS

500 Plaza Drive, Secaucus, NJ 07094 · Tel 973 520 2700 · questdiagnostics.com

INSIDERSTREET SCORE62 / 100Street mean $250.88 (8 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$17M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · DGX +25.8% · S&P 500 +15.9% · spread +9.9pp

7 Years vs S&P 500 · DGX +162.7% · S&P 500 +189.9% · spread -27.2pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE62of 100

Score Breakdown

Profitability	46/100
Growth	55/100
Momentum	83/100
Quality	75/100
Earnings Quality	77/100
Balance Sheet	51/100
Value	53/100
Risk (safety)	80/100
Overall	62.3/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
LH	62
GH	42
MTD	63
EXAS	50
MEDP	84
RVTY	50
DGX	62

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 67 in 25 Q3, latest 62 — -4 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY62 / 100IS Score 62.3 / 100 · -4.4 from peak of 67

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURELEAN BULLISHTechnical Score 62 / 100 · Power +23 · 17 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 62 and price structure at 62 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 62.3	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 67 → 65 → 64 → 62	the direction matters more than the level
Technical vote share back above 50%	now 73%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,102 → now 1,102	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)4 buys2026-09-04

Insider Buys (180d)0none disclosed

ETF Funds (30d)1051 up / 994 downnet +57 funds

Institutions Added (13F)42managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,102 · latest 1,102 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,102	105.6M	$20.8B	96.0%
2026 Q1	1,060	102.6M	$18.5B	93.2%
2025 Q4	1,042	105.9M	$16.9B	96.3%
2025 Q3	999	104.7M	$18.3B	95.2%
2025 Q2	984	107.1M	$17.7B	97.4%
2025 Q1	966	103.1M	$16.2B	93.7%
2024 Q4	892	99.0M	$13.9B	90.0%
2024 Q3	842	97.4M	$14.3B	88.6%
2024 Q2	834	97.1M	$13.1B	88.2%
2024 Q1	815	98.8M	$12.9B	89.8%
2023 Q4	821	97.1M	$12.8B	88.3%
2023 Q3	790	98.1M	$11.6B	89.2%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Wentworth Timothy C	director	2026-10-01	A-Award	135	—	477
Davis J. E.	director, CEO and President	2026-09-01	SELL	10,000	$2.43M	122,423
Prevoznik Michael E	SVP & General Counsel	2026-08-28	EXERCISE	22,677	$2.54M	60,234
Prevoznik Michael E	SVP & General Counsel	2026-08-28	SELL	16,010	$3.89M	44,224
Prevoznik Michael E	SVP & General Counsel	2026-08-28	SELL	6,237	$1.52M	37,987
Prevoznik Michael E	SVP & General Counsel	2026-08-28	SELL	430	$0.11M	37,557
Prevoznik Michael E	SVP & General Counsel	2026-08-28	GIFT	1,000	—	36,557
Prevoznik Michael E	SVP & General Counsel	2026-08-28	EXERCISE	22,677	$2.54M	0

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	15	78,911	$17.4M	Counted
M — Exercises (paired A/D)	3	30,824	$3.6M	None — mechanics
F — Tax withholding	15	54,681	$11.2M	None — compensation
G — Gifts	1	1,000	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$17.4M15 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-09-01	Davis J. E.	10,000	$2.4M
2026-08-28	Prevoznik Michael E	22,677	$5.5M
2026-07-28	Delaney Mark E	1,600	$0.4M
2026-06-04	Kuppusamy Karthik	8,147	$1.6M
Trailing 12 mo	24 filings	206,073	$42M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.53%	8.3M sh
2026-04-29	SCHEDULE 13G	Vanguard Portfolio Management	5.54%	6.1M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-08-14	SCHEDULE 13G/A	T. Rowe Price Associates, Inc.	6.50%	7.2M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
Julie Johnson	House	SELL	$1,001 - $15,000	2025-11-03	2025-12-12
Julie Johnson	House	SELL	$1,001 - $15,000	2025-11-03	2025-12-12
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-30	2026-07-20
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-21
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20

House 12-Mo9 trades4 purchases

Senate 12-Mo3 trades3 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,060

13F Shares103M93.2% of shares out

New / Closed124 / 86positions, QoQ

Increased / Reduced349 / 378positions, QoQ

Put/Call (13F)0.57option positions

Free Float99.5%110M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Artemis Investment Management Llp	334,585	$78M
Copeland Capital Management, Llc	104,830	$24M
Boston Common Asset Management, Ll	102,025	$24M
Fjarde Ap-Fonden /Fourth Swedish N	85,325	$20M
Jgp Wealth Management, Llc	66,685	$16M
Vontobel Holding Ltd.	59,231	$14M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$817M
VTSAX	0.0%	$817M
VSMPX	0.0%	$817M
VTI	0.0%	$817M
VFINX	0.0%	$676M
VOO	0.0%	$676M

13F Filers Holding DGX — quarterly

Institutional Put/Call — quarterly

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session34.5%2026-10-15

20-Day Avg52.2%50-day 60.0%

TrendFalling20d vs 50d

By Market CenterQ: 34% · N: 43% · B: 69%latest session

Weekly Notional ($B)

Where DGX Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.3M	34 sh
Ubsa Ubs Ats	1.0M	41 sh
Sgmt Sigma X2	0.7M	30 sh
Mstx Ms Trajectory Cross (Ats-1)	0.7M	24 sh
Ebxl Level Ats	0.6M	19 sh
Mlix Instinct X	0.5M	49 sh

Where a dollar of Quest Diagnostics Incorporated revenue goes. All values FY2025 filings, live.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

DGX (live moat model)Peer median: LH · GH · MTD · EXAS · MEDP

Component scores from the live moat model. Peer median illustrative.

Moat score 47/100 — Weak; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
James E. Davis	Chairman, Chief Executive Officer & President
Sam A. Samad	Executive Vice President & Chief Financial Officer
Catherine T. Doherty	Executive Vice President of Regional Businesses
Karthik Kuppusamy	Senior Vice President of Clinical Solutions

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+4.6%

Next Report2026-10-22

Income Quality1.61OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+14.3%	-8.4%	-6.4%	+6.7%	+11.8%
Gross profit	+15.9%	-18.4%	-10.6%	+5.7%	+8.6%
Operating income	+20.8%	-40.0%	-11.6%	+6.7%	+19.1%
Net income	+39.4%	-52.6%	-9.7%	+2.0%	+13.9%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	10.8	9.9	9.3	9.9	11.0
Cost of revenue	6.6	6.5	6.2	6.6	7.5
Gross profit	4.2	3.4	3.1	3.2	3.5
R&D expense	0.0	0.0	0.0	0.0	0.0
SG&A expense	1.7	1.9	1.6	1.8	2.0
Operating income	2.4	1.4	1.3	1.3	1.6
EBITDA	3.2	1.8	1.7	1.9	2.2
D&A	0.4	0.4	0.4	0.5	0.6
Pretax income	2.7	1.3	1.2	1.2	1.4
Income tax	0.6	0.3	0.2	0.3	0.3
Net income	2.0	0.9	0.9	0.9	1.0
Diluted EPS ($)	15.53	7.98	7.52	7.69	8.75
Diluted shares (M)	128	118	113	113	113

Operating CF$2B

CapEx$1B

Free cash flow$1B

SBC$0B

Buybacks$0B

Net cash change$-0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.3	0.7	0.5	0.4
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	1.2	1.2	1.3	1.4
Total current assets	1.9	2.4	2.4	2.4
PP&E (net)	2.4	2.4	2.8	2.9
Goodwill + intangibles	8.3	8.9	10.6	10.6
Total assets	12.8	14.0	16.2	16.2
Accounts payable	0.3	0.4	0.3	1.6
Short-term debt	0.2	0.6	0.9	0.7
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	1.6	1.8	2.2	2.3
Long-term debt	4.0	4.4	5.6	5.7
Total liabilities	6.8	7.6	9.3	8.9
Shareholders' equity	6.0	6.4	6.9	7.3

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	1.0	0.9	0.9	1.0
D&A	0.4	0.4	0.5	0.6
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	0.1	(0.1)	(0.2)	0.1
Operating cash flow	1.7	1.3	1.3	1.9
Capital expenditures	(0.4)	(0.4)	(0.4)	(0.5)
Investing cash flow	(0.5)	(1.1)	(2.5)	(0.6)
Buybacks	(1.4)	(0.3)	(0.2)	(0.5)
Dividends paid	(0.3)	(0.3)	(0.3)	(0.4)
Debt issuance / (repay)	(0.0)	0.7	1.5	(0.6)
Financing cash flow	(1.7)	0.2	1.1	(1.4)
Free cash flow	1.3	0.9	0.9	1.4

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	30.1%	15.3%	14.0%	13.3%	14.2%	14%
ROA	14.4%	7.1%	6.4%	5.8%	6.1%	6.3%
ROIC	17.9%	11.0%	8.9%	7.8%	8.8%	8.3%
Gross margin	39.0%	34.7%	33.2%	32.9%	31.9%	33.1%
Operating margin	22.1%	14.4%	13.6%	13.6%	14.5%	14.1%
Net margin	18.5%	9.6%	9.2%	8.8%	9.0%	9.2%
EBITDA margin	29.3%	18.4%	18.7%	19.2%	19.9%	19.3%
FCF margin	17.0%	13.3%	9.3%	9.2%	12.3%	—
VALUATION
P/E	10.04	17.98	17.53	19.21	19.50	24.6
P/B	3.10	2.87	2.37	2.47	2.70	3.4
P/S	1.85	1.71	1.62	1.69	1.75	2.24
P/FCF	10.91	12.89	17.33	18.41	14.24	21.3
EV/EBITDA	7.56	11.74	11.42	12.28	11.87	14.2
EV/Revenue	2.21	2.16	2.14	2.36	2.34	2.7
Earnings yield	10.0%	5.6%	5.7%	5.2%	5.1%	4.11%
FCF yield	9.2%	7.8%	5.8%	5.4%	7.0%	4.70%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.56	1.22	1.31	1.10	1.04	1.59
Quick ratio	1.44	1.10	1.20	1.02	0.96	1.46
Debt / equity	0.74	0.80	0.87	1.05	0.96	0.85
Debt / assets	35.1%	36.7%	39.2%	43.9%	42.6%	37.7%
Net debt / EBITDA	1.23	2.42	2.78	3.45	2.99	2.59
Interest coverage	18.10	9.34	7.93	6.20	5.80	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.78	0.75	0.69	0.65	0.68	0.68
Receivables turnover	7.29	7.51	7.69	7.85	8.14	6.9
DSO (days)	50	49	47	46	45	53
DPO (days)	22	19	21	18	47	—
Cash conversion cycle	40	41	38	39	7	64
GROWTH (YoY)
Revenue growth	14.3%	-8.4%	-6.4%	6.7%	11.8%	—
Net income growth	39.5%	-52.6%	-9.3%	2.0%	13.9%	—
EPS growth	52.9%	-48.5%	-7.7%	2.0%	14.9%	—
FCF growth	15.3%	-28.2%	-34.2%	5.2%	49.5%	—
PER SHARE ($)
EPS (diluted, TTM)	15.90	8.19	7.56	7.71	8.86	9.65
Book value / share	51.55	51.24	55.81	59.98	64.02	71.08
Revenue / share	86.30	85.94	81.88	87.36	98.53	105.09
FCF / share	14.64	11.43	7.65	8.04	12.13	11.09
Cash / share	6.98	2.74	6.07	4.86	3.75	5.69
SHAREHOLDER RETURN & SCORES
Buyback yield	11.0%	8.3%	2.1%	0.9%	2.3%	2.33%
Altman Z-Score	4.03	3.55	3.07	2.81	3.18	3.6
Piotroski F-Score	6	4	5	5	7	7/9
Beneish M-Score	-2.57	-2.91	-2.54	-2.49	-2.66	-2.51

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	3.6	Safe (>2.99)	Safe
Income quality	1.61	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.51	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.75
Interest burden	0.86
Operating margin	14.2%
Asset turnover	0.70×
Financial leverage	2.23×
= ROE	14%

Growth Quality (live)	Value
Revenue stability	0.03
Earnings stability	0.51
Earnings persistence	0.95
Revenue CAGR 3y	6.8%
EPS CAGR 3y	10.9%
FCF CAGR 3y	11.6%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield2.33%

Dividend Yield1.44%

Total Shareholder Return3.79%cash yield

SBC / Revenue0.5%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
LH	$25.8B	26.1	12%	8.0%	+6.4%	8/9	+13.2%
GH	$21.3B	-45.4	172%	-35.9%	+42.7%	6/9	+135.1%
MTD	$32.5B	36.4	-736%	22.7%	+6.9%	8/9	+19.2%
EXAS	$20.0B	-188.6	-9%	-9.8%	+17.7%	7/9	+119.7%
MEDP	$17.3B	35.6	162%	17.2%	+24.7%	8/9	—
RVTY	$17.0B	72.7	3%	7.1%	+5.5%	6/9	—
ILMN	$39.6B	48.5	32%	17.9%	+4.9%	7/9	—
WAT	$42.9B	108.7	2%	-8.3%	+52.5%	5/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

34 Analysts

Str Sell (0)Sell (3)Hold (18)Buy (13)Str Buy (0)

Mean Target (qtr)$250.888 targets

Target vs. Price+6.8%last-quarter mean

Next Report2026-10-22street $2.87

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$12.01B	$12.10B / $11.98B	$11.20	$11.24 / $11.17	11
FY2027	$12.56B	$12.77B / $12.47B	$12.04	$12.32 / $11.80	11
FY2028	$13.10B	$13.34B / $12.85B	$13.07	$14.15 / $12.13	8

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$260.00	+10.6%	2
Last Quarter	$250.88	+6.8%	8
Last Year	$226.76	-3.5%	25
All Time	$196.13	-16.5%	56

Rolling mean of published targets vs. last close $235.00. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

4/5

ROE

4/5

ROA

5/5

Debt/Eq

1/5

P/E

2/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

DGX +25.8% vs S&P 500 +15.9% — spread +9.9pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$233.16	+1.84	+0.79%	Above
SMA 50	$237.24	-2.24	-0.94%	Below
SMA 200	$208.70	+26.30	+12.60%	Above
EMA 9	$233.57	+1.43	+0.61%	Above
EMA 21	$234.00	+1.00	+0.43%	Above
EMA 50	$232.73	+2.27	+0.98%	Above
EMA 200	$212.65	+22.35	+10.51%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTLEAN BULLISHPower Score +2317 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%40

Momentum 25%90

Volume 20%81

Volatility 10%50

Patterns 15%38

This Week73% bullishof 11 price-based votes

4 Weeks Ago100%-27 pts since

12 Weeks Ago100%-27 pts since

ReadDeterioratingweek-over-week trajectory

Price vs SMA 20$233.16

Price vs SMA 50$237.24

Price vs SMA 200$208.70

EMA 9/21 Cross233.6/234.0

SMA 50/200Golden

ADX DirectionADX 25

Supertrend$244

Parabolic SAR$226

SMA Slope-0.570

RSI51.1

Stochastic K/D76/67

StochRSI K/D89/87

Williams %R-37

CCI78

TSI vs Signal-4.6

CMO2.2

ROC1.09%

OBV SignalAccum

Chaikin MF0.030

MFI53

Force Index0M

Elder Ray Bull6.48

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 67

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$237.96 / $240.36 / $241.56	S1 / S2	$236.76 / $234.36
Bollinger (20,2)	$225.71 – $240.61	Squeeze	ON
52-wk range	$170.40 – $248.70	Off 52-wk high	-5.5%
ATR (14)	$5.24 (2.2%)	Historical vol	24.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-0.2%Jan50%

-1.2%Feb30%

+1.0%Mar62%

+3.5%Apr60%

+1.9%May60%

+1.4%Jun60%

+0.9%Jul55%

-0.7%Aug55%

-0.2%Sep40%

+0.4%Oct50%

+2.9%Nov70%

+1.0%Dec65%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	DGX	S&P 500
Weekly volatility (σ, 1y)	3.67%	1.83%
Best / worst week (1y)	+12.1% / -4.7%	—
Max drawdown (5y, monthly)	-33.3%	—
1-week VaR (95%)	-4.0%	—
Beta (5y)	0.55	1.00

DGX EQUITY WEATHER (LIVE)RAINY · -19

Trend-22

Momentum+20

Volume-47

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 183 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall-18.6-1.6 vs industry

Trend-22.3-15.1 vs industry

Momentum+19.9+46.8 vs industry

Volume-46.9-46.9 vs industry

Reading	DGX	Medical - Diagnostics & Research n=227	Healthcare n=5,272	All US symbols n=70,435
Overall	-18.6	-17.0	-24.0	-20.5
Trend	-22.3	-7.2	-25.6	-21.3
Momentum	+19.9	-27.0	-28.5	-15.8
Volume	-46.9	+0.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
James E. Davis Chairman, Chief Executive Off	$15.5M	71% equity+incentive
Sam A. Samad Executive Vice President and Ch	$4.4M	66% equity+incentive
Catherine T. Doherty Executive Vice Presiden	$3.6M	64% equity+incentive
Karthik Kuppusamy Senior Vice President, Cli	$2.6M	61% equity+incentive
Michael E. Prevoznik Senior Vice President a	$2.6M	61% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	64
Social	60
Governance	65
Composite ESG	63

Composite ESG Trend

Filed	8-K contents	Items
2026-10-06	Officer/Director Change	5.02
2026-07-23	Earnings Release; Exhibits	2.02,9.01
2026-05-21	Shareholder Vote	5.07
2026-05-08	Material Agreement; Exhibits	1.01,9.01
2026-05-01	Other Events; Exhibits	8.01,9.01
2026-04-21	Earnings Release; Exhibits	2.02,9.01
2026-03-12	Departure/Election of Directors; Appointment of Officers; Regulation F	5.02,7.01,9.01
2026-02-10	Results of Operations and Financial Condition; Other Events; Financial	2.02,8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-07-23 to 2026-04-21
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	114 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-07-22 to 2026-10-01
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-08-14 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Quest Diagnostics Incorporated (DGX)

Institutions holding — 12 quarters

Quest Diagnostics Incorporated (DGX)

Monthly Net Insider Flow (000 shares)

Signal Summary

Quest Diagnostics Incorporated (DGX)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding DGX — quarterly

Institutional Put/Call — quarterly

Quest Diagnostics Incorporated (DGX)

Where DGX Trades in the Dark

Quest Diagnostics Incorporated (DGX)

3.8 · Employees (SEC filings)

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Balance Sheet — Full

Cash Flow Statement — Full

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Street Price Target — Trajectory

Third-Party Composite Rating

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Family Scores (site weights)

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX)